Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tertatolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 5/20 | 0.98 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.98 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.98 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.98 |
| ▸ | ADRB2 known ✓ | P07550 | 9/20 | 0.55 |
| ▸ | ADRB1 known ✓ | P08588 | 6/20 | 0.55 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.55 |
| ▸ | ADRB3 known ✓ | P13945 | 2/20 | 0.53 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.53 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.52 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.52 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.52 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.52 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.52 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.52 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.50 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.49 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.49 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tertatolol SCHEMBL388069 | 1.00 | HTR1A (0.98) | HTR1ASLC6A4ADRA2ASLC6A2ADRB2 | |
| Tertatolol SCHEMBL49635 | 0.99 | HTR1A (1.00) | HTR1ASLC6A4ADRA2ASLC6A2ADRB2 | |
| Tertatolol SCHEMBL6513139 | 0.99 | HTR1A (1.00) | HTR1ASLC6A4ADRA2ASLC6A2ADRB2 | |
| Tertatolol SCHEMBL49634 | 0.99 | HTR1A (1.00) | HTR1ASLC6A4ADRA2ASLC6A2ADRB2 | |
| Tertatolol SCHEMBL23234262 | 0.98 | HTR1A (0.98) | HTR1ASLC6A4ADRA2ASLC6A2ADRB2 | |
| Tertatolol SCHEMBL1649964 | 0.97 | HTR1A (0.96) | HTR1ASLC6A4ADRA2ASLC6A2ADRB2 | |
| SCHEMBL9123669 | 0.84 | HTR1A (0.74) | HTR1ASLC6A4ADRA2ASLC6A2ADRB2 | |
| Tertatolol SCHEMBL9136272 | 0.84 | HTR1A (0.72) | HTR1ASLC6A4ADRA2ASLC6A2ADRB2 | |
| Hydrochloric Acid SCHEMBL11231605 | 0.81 | ADRB2 (0.67) | HTR1ASLC6A4ADRA2ASLC6A2ADRB2 | |
| SCHEMBL9507435 | 0.81 | SLC6A2 (0.70) | HTR1ASLC6A4ADRA2ASLC6A2ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150352094-A1 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | CATABASIS PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | claimed |
| EP-2941252-A2 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | Catabasis Pharmaceuticals, Inc. (US) | 2015-11-11 | — | — | EP | claimed |
| WO-2014107730-A2 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | WO | claimed |
| US-8642089-B2 | Melt extrusion of salts of active ingredients | EVONIK ROEHM GMBH (DE) | 2014-02-04 | — | — | US | claimed |
| EP-1064935-B2 | Solid delayed-release pharmaceutical compositions prepared by means of a thermoforming process | SERVIER LAB (FR) | 2011-06-08 | — | — | EP | claimed |
| EP-1064935-B1 | Solid controlled-release pharmaceutical compositions prepared by means of a thermoforming process | SERVIER LAB (FR) | 2008-05-14 | — | — | EP | claimed |
| EP-1478344-B1 | MELT EXTRUSION CONSISTING OF SALTS OF ACTIVE INGREDIENTS | ROEHM GMBH (DE) | 2007-05-23 | — | — | EP | claimed |
| CN-1780823-A | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC (JP) | 2006-05-31 | — | — | CN | claimed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | claimed |
| US-20040253314-A1 | Melt extrusion of salts of active ingredients | ROEHM GMBH (DE) | 2004-12-16 | — | — | US | claimed |
| EP-1478344-A2 | MELT EXTRUSION CONSISTING OF SALTS OF ACTIVE INGREDIENTS | Röhm GmbH & Co. KG (DE) | 2004-11-24 | — | — | EP | claimed |
| WO-2003072083-A2 | MELT EXTRUSION CONSISTING OF SALTS OF ACTIVE INGREDIENTS | Röhm GmbH & Co. KG (DE) | 2003-09-04 | — | — | WO | claimed |
| US-6319520-B1 | COPOLYMERS OF AMMONIUM METHACRYLATE THAT CONSIST OF FULLY POLYMERIZED COPOLYMERS OF ACRYLIC ACID AND METHACRYLIC ACID ESTER HAVING QUATERNARY AMMONIUM GROUPS | ADIR ET COMPAGNIE (FR) | 2001-11-20 | — | — | US | claimed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20250026719-A1 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| EP-1354888-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| WO-2003072083-A2 | MELT EXTRUSION CONSISTING OF SALTS OF ACTIVE INGREDIENTS | Röhm GmbH & Co. KG (DE) | 2003-09-04 | — | — | WO | disclosed |
| US-6319520-B1 | COPOLYMERS OF AMMONIUM METHACRYLATE THAT CONSIST OF FULLY POLYMERIZED COPOLYMERS OF ACRYLIC ACID AND METHACRYLIC ACID ESTER HAVING QUATERNARY AMMONIUM GROUPS | ADIR ET COMPAGNIE (FR) | 2001-11-20 | — | — | US | disclosed |
| WO-1995020568-A1 | PHARMACEUTICAL PRODUCT COMPRISING A SALICYLATE OF AN ESTERIFIABLE BETA-BLOCKER | CAL INTERNATIONAL LIMITED (IE) | 1995-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026719-A1 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | PCSK9, PCSK7, PCSK6 | HTR1A 3469/4885SLC6A4 4839/4885ADRA2A 2260/4885 |
| US-20150352094-A1 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | NAMPT, NNT, FASN | HTR1A 2260/4885SLC6A4 667/4885ADRA2A 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.